Publication: Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia
Issued Date
2013-05-01
Resource Type
ISSN
18735835
01452126
01452126
Other identifier(s)
2-s2.0-84875889772
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Leukemia Research. Vol.37, No.5 (2013), 520-530
Suggested Citation
Daniela Cilloni, Sonia Carturan, Enrico Bracco, Valentina Campia, Valentina Rosso, Davide Torti, Chiara Calabrese, Valentina Gaidano, Pimjai Niparuck, Alessandra Favole, Elisabetta Signorino, Ilaria Iacobucci, Annalisa Morano, Luciana De Luca, Pellegrino Musto, Francesco Frassoni, Giuseppe Saglio Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leukemia Research. Vol.37, No.5 (2013), 520-530. doi:10.1016/j.leukres.2013.01.014 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/31321
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia
Abstract
Chronic myelomonocytic leukemia (CMML) is a clonal disorder sharing features of myelodysplastic syndromes and chronic myeloproliferative neoplasms. Although rare chromosomal aberrations and point mutations are reported in CMML, the molecular defects underlying CMML are largely unknown. ROS1 encodes a tyrosine kinase that is abnormally expressed and translocated in brain and lung cancers. In this study we show that ROS1 is abnormally activated in the CD34+ compartment of approximately 70% of CMML patients resulting in the activation of the Erk/Akt pathways through the Grb2/SOS complex thus revealing a central oncogenic role for ROS1 in CMML which might represent a molecular target. © 2013 Elsevier Ltd.